| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-582SS | |||
| Azide and BSA Free | NBP2-80959 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2215SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-600SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-302SS | |||
| Azide and BSA Free | NBP2-80675 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-103SS | |||
| Azide and BSA Free | NBP2-80898 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-37235SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-85816-25ul | |||
![Western Blot: SREBP1 Antibody (2A4) [NB600-582] - Hepatic SREBP1c and SREBP2 protein abundance in C57BL/6 mice assigned to a high-fat (HF) or a high-fat/exercise (HF + EX) group for 8 weeks. Cytosolic and nuclear SREBP1c abundance. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/jl/2013/908048/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Western-Blot-NB600-582-img0004.jpg "Western Blot: SREBP1 Antibody (2A4) [NB600-582] - Hepatic SREBP1c and SREBP2 protein abundance in C57BL/6 mice assigned to a high-fat (HF) or a high-fat/exercise (HF + EX) group for 8 weeks. Cytosolic and nuclear SREBP1c abundance. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/jl/2013/908048/), licensed under a CC-BY license.")
![Western Blot: SREBP1 Antibody (2A4) [NB600-582] - Analysis of whole cell lysate from HeLa cells showing a single specific band for the expression of SREBP1 precursor protein (~120 kDa).](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Western-Blot-NB600-582-img0002.jpg)
![Simple Western: SREBP1 Antibody (2A4) [NB600-582] - Lane view shows a specific band for SREBP1 in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Simple-Western-NB600-582-img0003.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: SREBP1 Antibody (2A4) [NB600-582] - KO and OE of SREBP1 influenced lipid metabolism in Bel-7402 cells. The protein level of lipid-associated genes in SREBP1-KO, SREBP1-OE, and WT Bel-7402 cells. Data were expressed as mean -/+ standard error of the mean. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. WT group, respectively.](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Knockout-Validated-NB600-582-img0005.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - Effect of GEN on the expression of Nrf2‐related signalling proteins in OA (660 μmol/L) & PA (330 μmol/L)‐induced HepG2 cells. GEN was added into HepG2 cells prior 1 h to stimulation of OA & PA for 18 h. A‐C, Protein expression of Nrf2, PPAR alpha , PPAR gamma in nucleus & HO‐1 in cytoplasm was detected by Western blot. (D & E) Protein expression of P‐ACC, ACC, P‐AKT, AKT, P‐AMPK alpha , AMPK alpha , P‐AMPK beta & AMPK beta was detected by Western blot. F‐H, Protein expression of PI3K, P‐mTORC, mTORC, P‐S6K, S6K, P‐S6, S6, SREBP‐1c & HMGB1 was detected by Western blot. The similar results were collected from three dependent experiments. All data were expressed by mean ± SEM (n = 5 in each group). ##P < .01 vs Control Group; *P < .05 & **P < .01 vs OA & PA Group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32293113), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-31020241534375.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - KO & OE of SREBP1 influenced lipid metabolism in Bel-7402 cells. (A) Total cellular TG content of SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. (B) HPLC-MS determination of the SFAs to MUFAs ratios (palmitic acid to palmitoleic acid, 16:0 to 16:1) (stearic acid to oleic acid, 18:0 to 18:1) as well as the content of 16:0, 16:1, 18:0, & 18:1 in SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. (C) The transcript level of lipid-associated genes in SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. (D & E) The protein level of lipid-associated genes in SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. Data were expressed as mean ± standard error of the mean. *P < 0.05, **P < 0.01, & ***P < 0.001 vs. WT group, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31297058), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202415384185.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - Construction of knockout (KO) & overexpression (OE) cell lines. (A) The sequencing results of KO positive clone cells; (B) The messenger RNA (mRNA) level of SREBP1 in wild type (WT) & OE Bel-7402 cells. Data were expressed as mean ± standard error of the mean. ***P < 0.001 vs. WT group; (C & D) The protein level of SREBP1 in WT, OE, & KO Bel-7402 cells. Data were expressed as mean ± standard error of the mean. ***P < 0.001 vs. WT group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31297058), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-31020241539748.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - p75NTR stimulation activated SREBP1 & SREBP2 in Huh7 hepatocyte cells.Human Huh7 cells were stimulated with 10 ng/ml pro-NGF or 50 ng/ml NGF for 16 h followed by immunoblotting using antibodies to detect the presence of cleaved/activated SREBP1 & SREBP2. a SREBP1, immunoblots & b quantification. Values are mean ± SD, n = 3. **P < 0.01 & *p < 0.05 for treated vs. control cells. c, d SREBP2. Cells were treated with 10 ng/ml pro-NGF in the absence or presence of 0.5 μM PF429242 (PF), which is a selective inhibitor of the Site 1 protease (S1P). c Immunoblots & d quantification. PF decreased the amount of processed SREBP2 in these cells; however, addition of pro-NGF increased the relative level of cleaved SREBP2. Values are mean ± SD, n = 3. *p < 0.05 for treated vs. the corresponding control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31296846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202416161836.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - p75NTR stimulation activated SREBP1 & SREBP2 in Huh7 hepatocyte cells.Human Huh7 cells were stimulated with 10 ng/ml pro-NGF or 50 ng/ml NGF for 16 h followed by immunoblotting using antibodies to detect the presence of cleaved/activated SREBP1 & SREBP2. a SREBP1, immunoblots & b quantification. Values are mean ± SD, n = 3. **P < 0.01 & *p < 0.05 for treated vs. control cells. c, d SREBP2. Cells were treated with 10 ng/ml pro-NGF in the absence or presence of 0.5 μM PF429242 (PF), which is a selective inhibitor of the Site 1 protease (S1P). c Immunoblots & d quantification. PF decreased the amount of processed SREBP2 in these cells; however, addition of pro-NGF increased the relative level of cleaved SREBP2. Values are mean ± SD, n = 3. *p < 0.05 for treated vs. the corresponding control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31296846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202416175210.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - Effect of GEN on the protein expression of Nrf2, ACC & mTORC signalling pathways in tyloxapol‐induced mice. GEN (50, 75, 100 mg/kg) was administered to WT or Nrf2−/− mice prior 1 h to stimulation of tyloxapol (500 mg/kg) for 18 h. A‐C, Protein expression of Nrf2, PPAR alpha , PPAR gamma in nucleus & HO‐1 in cytoplasm of WT mice was detected by Western blot. (D & E) Protein expression of Nrf2, PPAR alpha & PPAR gamma in Nrf2−/− mice was detected by Western blot. F‐H, Protein expression of P‐ACC, ACC, P‐AKT, AKT, P‐AMPK alpha , AMPK alpha , P‐AMPK beta , AMPK beta in WT & Nrf2−/− mice was detected by Western blot. I‐M, Protein expression of PI3K, P‐mTORC, mTORC, P‐S6K, S6K, P‐S6, S6, SREBP‐1c & HMGB1 WT & Nrf2−/− mice was detected by Western blot. The similar results were collected from three dependent experiments. All data were expressed by mean ± SEM (n = 5 in each group). ##P < .01 vs Control group; *P < .05 & **P < .01 vs Tyloxapol group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32293113), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202416171460.jpg)
![Simple Western: SREBP1 Antibody [NB100-2215] - Image shows a specific band for SREBP1 in 1 mg/mL of HeLa cell lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Simple-Western-NB100-2215-img0007.jpg "Simple Western: SREBP1 Antibody [NB100-2215] - Image shows a specific band for SREBP1 in 1 mg/mL of HeLa cell lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-2215] - CDC2 associates with SPDY at ERES. (A-C) 0 h GV stage oocyte labeled for CDC2 (A, green), DNA (A, blue), and SPDY (B, red). Both CDC2 and SPDY localize to the same cortical domain (C). Note that the center of this oocyte is dented (the area that contains the arrow) causing the structure to appear in the middle of the oocyte, whereas it is located in the cortex. Images are Z-projections of 2 (A-C); scale bars represent 20 um in C and 5 um in C'. Arrows indicate the region of the oocyte that is shown enlarged in the insets (B'-C'). Arrowheads denote the position of the GV. Image collected and cropped by CiteAb from the following publication (//bmcdevbiol.biomedcentral.com/articles/10.1186/1471-213X-9-8) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2215-img0011.jpg)
![Western Blot: SREBP1 Antibody [NB100-2215] - MiR-181a overexpression impairs and miR-181a inhibition improves glucose and lipid homeostasis in HepG2 cellsHepG2 cells were divided into 4 groups as follows: a control group, mimics group (HepG2 cells transfected with 10 nM mimics), NEFA group (treated with 1. 2 mM NEFA), and miR-181a + NEFA group (transfected with 50 nM miR-181a inhibitors and then treated with 1. 2 mM NEFA). It was followed with or without 100 nM insulin. Immunoblot analysis (left) and quantification (right) of SREBP-1c and PPARI+- in HepG2 cells. Image collected and cropped by Citeab from the following publication (Upregulation of miR-181a impairs hepatic glucose and lipid homeostasis. Oncotarget (2017)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Western-Blot-NB100-2215-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-2215] - SREBP1 antibody was tested in HeLa cells with DyLight488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Nuclear and punctate vesicle staining was observed.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2215-img0006.jpg)
![Immunohistochemistry-Paraffin: SREBP1 Antibody [NB100-2215] - nalysis of FFPE tissue section of mouse liver with SREBP1 antibody at 1:200. The antibody generated an expected cytoplasmic-nuclear immunostaining of SREBP1 protein in the hepatocytes.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunohistochemistry-Paraffin-NB100-2215-img0008.jpg)
![Western Blot: SREBP1 Antibody [NB100-2215] - Detection of SREBP1. Lane 1: human liver. Lane 2: mouse liver.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Western-Blot-NB100-2215-img0004.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression impairs & miR-181a inhibition improves glucose & lipid homeostasis in HepG2 cellsHepG2 cells were divided into 4 groups as follows: a control group, mimics group (HepG2 cells transfected with 10 nM mimics), NEFA group (treated with 1.2 mM NEFA), & miR-181a + NEFA group (transfected with 50 nM miR-181a inhibitors & then treated with 1.2 mM NEFA). B was followed with or without 100 nM insulin. (A) Immunoblot analysis (top) & quantification (bottom) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in HepG2 cells. (B) Immunoblotting analysis (top) & quantification (bottom) of insulin-stimulated phosphorylation of AKT in HepG2 cells. (C) Glucose concentration in medium. (D) The glycogen content in HepG2 cells. (E) The mRNA expression levels of G6Pase & PEPCK. (F) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha in HepG2 cells. (G) TG content in HepG2 cells. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241682194.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - Effect of restoration of macrophage A2bAR on liver.Liver was collected from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD as described in the methods. Relative mRNA expression was determined using the delta delta CT method with normalization to 18s rRNA. A. mRNA expression of TNF-alpha in liver. A2bAR KO (n = 5) vs WT (n = 7) p-value = 0.0271; A2bAR KO vs CD68-Tg (n = 6) p-value = 0.0210. B. mRNA expression of IL-6 in liver. A2bAR KO (n = 8) vs WT (n = 7) p-value = 0.0159; A2bAR KO vs CD68-Tg (n = 8) p-value = 0.0080. C. mRNA expression of IRS-2 in liver. CD68-Tg (n = 7) vs A2bAR KO (n = 8) p-value = 0.0300. D. Western blot analysis of liver; one representative (of 3 sets) WT, CD68-Tg & A2bAR KO group shown at 15 minutes post-insulin injection, following 16 weeks of HFD. Levels of mature SREBP-1 (68 kDa), & IRS-2 (185 kDa), were probed by Western blot analysis, using beta -actin (43 kDa) as loading control. Quantification of Western Blot results was performed with Image J software (//rsb.info.nih.gov/ij/) with normalization to beta -actin. WT to A2bAR KO: IRS-2 p-value = 0.0092, SREBP-1 p-value = 0.0154; CD68-Tg to A2bAR KO: IRS-2 p-value = 0.0247, SREBP-1 p-value = 0.0170. Data are averages ± SD. *Student two-tail t-test assuming equal variance was found significant only when p-value <0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24892847), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241682175.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression or SIRT1 knockdown impairs glucose & lipid metabolism in vivo(Aa & Ab) Immunoblotting analysis (left) & quantification (right) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in the liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (B) Glucose tolerance test of mice injected with Ago-181a (n = 7) or Ago-NC (n = 7) or Ad-shRNA NC (n = 6) or Ad-shRNA SIRT1 (n = 6). (C) Insulin tolerance test of mice injected with Ago-181a (n = 7) or Ago-NC (n = 7) or Ad-shRNA NC (n = 6) or Ad-shRNA SIRT1 (n = 6). (D) Representative images of PAS staining (original magnification × 20) of liver sections from mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (Ea & Eb) Immunoblotting analysis (top) & quantification (bottom) of insulin-stimulated phosphorylation of IR, AKT & GSK3 beta in liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (F) Representative images of H&E staining (left, original magnification × 20) & Oil-red staining (right, original magnification × 20) of liver sections from mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (Ga & Gb) Immunoblotting analysis (top) & quantification (bottom) of SREBP-1c & PPAR alpha in the liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241553209.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression impairs & miR-181a inhibition improves glucose & lipid metabolism in vitro(A, B, C, D & E) Hepatocytes were transfected with 10 nM miR-181a mimics or negative controls in the absence or presence of 100 nM insulin. (A) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta in hepatocytes. (B) The mRNA expression levels of G6Pase & PEPCK in hepatocytes. (C) Glucose concentration in medium. (D) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha expression in hepatocytes. (E) TG content in hepatocytes. (F, G, H, I & J) Hepatocytes were transfected with 50 nM miR-181a inhibitors or negative controls in the absence or presence of 100 nM insulin. (F) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta in hepatocytes. (G) The expression levels of G6Pase & PEPCK in hepatocytes. (H) Glucose concentration in medium. (I) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha expression in hepatocytes. (J) TG content in hepatocytes. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-310202415535169.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - Effect of restoration of macrophage A2bAR on adipose tissue.Visceral (epididymal) adipose tissue was collected from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD as described in the methods. A-C,E. Relative mRNA expression was determined using the delta delta CT method with normalization to 18s rRNA. A. mRNA expression of TNF-alpha in visceral fat. A2bAR KO (n = 7) vs CD68-Tg (n = 9) p-value = 0.0345. B. mRNA expression of IL-6 in visceral fat. A2bAR KO (n = 7) vs WT (n = 7) p-value = 0.0073; A2bAR KO vs CD68-Tg (n = 7) p-value = 0.0141. C. mRNA expression of MCP1 in visceral fat. A2bAR KO (n = 7) vs CD68-Tg (n = 9) p-value = 0.0232. D. Visceral adipose tissue from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD was fixed in 4% paraformaldehyde & paraffin-embedded. Sections immunostained with the macrophage marker F4/80. Representative sections for each genotype at a magnification of 200x & 400x. Arrows point to crown-like structures. E. mRNA expression of IRS-2 in visceral fat. CD68-Tg (n = 8) vs A2bAR KO (n = 8) p-value = 0.0115, WT (n = 6) vs A2bAR KO p-value = 0.0358. F. Western blot analysis of visceral fat; one representative (of 3 sets) WT, CD68-Tg & A2bAR KO group shown at 15 minutes post-insulin injection, following 16 weeks of HFD. WT to A2bAR KO: IRS-2 p-value = 0.0411, SREBP-1 p-value = 0.0103. CD68-Tg to A2bAR KO: IRS-2 p-value = 0.0305, SREBP-1 p-value = 0.0459. Data are averages ± SD. *Student two-tail t-test assuming equal variance was found significant only when p-value <0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24892847), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241682189.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - SIRT1 knockdown impairs & SIRT1 overexpression improves glucose & lipid metabolism in hepatocytes(A) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta protein levels in hepatocytes. Hepatocytes were transfected with SIRT1 siRNA with or without 100 nM insulin. (B) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha protein levels in hepatocytes. Hepatocytes were transfected with SIRT1 siRNA. (C) Immunoblot analysis (left) & quantification (right) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in hepatocytes. Hepatocytes were infected with Ad-SIRT1. (D) Immunoblotting analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, AKT & GSK3 beta in hepatocytes. Hepatocytes were treated with 1.2 mM NEFA or 1.2 mM NEFA & Ad-SIRT1 with or without 100 nM insulin. (E, F & G) Hepatocytes were treated with 1.2 mM NEFA or 1.2 mM NEFA & Ad-SIRT1. (E) Glucose concentration in medium. (F) Immunoblot analysis (top) & quantification (bottom) of SREBP-1c & PPAR alpha in hepatocytes. (G) TG contents in hepatocytes. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-310202415541953.jpg)
![Immunohistochemistry: GLI-1 Antibody - BSA Free [NB600-600] - GLI-1 Antibody [NB600-600] - Inhibition of Hh signaling in CAFs blocks its effects on lymphangiogenesis in vivo and in vitro. (E) IHC staining for Ki-67, -SMA, Gli-1 and LYVE1 in tumour sections from mice in the two groups. Human CAFs promote lymphangiogenesis in ovarian cancer via the Hh-VEGF-C signaling axis. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31012844/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GLI-1-Antibody-Immunohistochemistry-Paraffin-NB600-600-img0005.jpg "<b>Genetic Strategies Validation. </b>Immunohistochemistry: GLI-1 Antibody - BSA Free [NB600-600] - GLI-1 Antibody [NB600-600] - Inhibition of Hh signaling in CAFs blocks its effects on lymphangiogenesis in vivo and in vitro. (E) IHC staining for Ki-67, -SMA, Gli-1 and LYVE1 in tumour sections from mice in the two groups. Human CAFs promote lymphangiogenesis in ovarian cancer via the Hh-VEGF-C signaling axis. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31012844/) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry-Paraffin: GLI-1 Antibody [NB600-600] - Analysis of a FFPE mouse brain section using GLI-1 antibody at 1:600 dilution.](http://images.novusbio.com/fullsize/GLI-1-Antibody-Immunohistochemistry-Paraffin-NB600-600-img0003.jpg)
![Immunohistochemistry-Paraffin: GLI-1 Antibody [NB600-600] - Staining in canine hair follicle. Image from a verified customer review.](http://images.novusbio.com/fullsize/GLI-1-Antibody-Immunohistochemistry-Paraffin-NB600-600-img0004.jpg)
![Flow (Intracellular): GLI-1 Antibody [NB600-600] - Staining for GLI-1 in untreated human B cell lines (BCWM.1, MWCL-1 and RPCI-WM1) using anti-GLI-1 antibody. Rabbit IgG Isotype Control (Cat# NBP2-36463) was used as a negative control. Image courtesy of Sherine Elsawa, Northern Illinois University.](http://images.novusbio.com/fullsize/GLI-1-Antibody-Flow-Intracellular-NB600-600-img0002.jpg)
![Immunohistochemistry-Paraffin: GLI-1 Antibody - BSA Free [NB600-600] - Paracrine signaling of tumour-derived SHH in CAFs promotes lymphangiogenesis in vivo(A) Growth properties of subcutaneous tumours in mice derived from Caov3 SHH-OE or Caov3 NC cells alone or co-injected with CAFs. Kaplan-Meier plot of time to tumour progression, as evidenced by survival rates over time (n=5). (B) Bright field images of subcutaneous tumours from each group (n=5) 20 days after tumour implantation. (C) Graphical representation of the weights of subcutaneous tumours from each group 20 days after tumour implantation. (D) Immunohistochemical staining for Ki-67, alpha -SMA, Gli-1 & LYVE1 in tumour sections from mice in each group. (E) Graphical representation of the number of LYVE1+ vessels counted from IHC images in panel D. (*P<0.05, **P<0.01, ***P<0.001). Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.18621), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-600_rabbit-polyclonal-gli-1-antibody-31020241618947.jpg)
![Immunohistochemistry-Paraffin: GLI-1 Antibody - BSA Free [NB600-600] - Inhibition of Hh signaling in CAFs blocks its effects on lymphangiogenesis in vivo & in vitro(A) Representative images & statistical analyses of migration of LECs in a co-culture invasion system with CAFs stably transfected with shNC or Gli-shRNA lentivirus in the presence of rSHH (1 μg/ml). (B) Representative images & statistical analyses of capillary tube formation of LECs treated with supernatants from cultures of CAFs stably transfected with shNC or Gli-shRNA lentivirus in the presence of rSHH (1 μg/ml). (C) Bright field images & graphical representation of the weights of tumours of subcutaneous tumours from mice (n=5) bearing Caov3 SHH-OE cells co-injected with CAFs stably transfected with shNC or Gli-shRNA lentivirus 20 days after tumour implantation. (D) Growth properties of subcutaneous tumours in mice derived from Caov3 SHH-OE cells co-injected with CAFs stably transfected with shNC or Gli-shRNA lentivirus. Kaplan-Meier plot of time to tumour progression, as evidenced by survival rates over time. (E) IHC staining for Ki-67, alpha -SMA, Gli-1 & LYVE1 in tumour sections from mice in the two groups. (F) Graphical representation of the number of LYVE1+ vessels counted from IHC images in panel E. (**P<0.01, ***P<0.001). Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.18621), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-600_rabbit-polyclonal-gli-1-antibody-310202416175276.jpg)
![Western Blot: YAP1 Antibody (2F12) - Isoform 5 [H00010413-M01] - YAP1 Antibody (2F12) [H00010413-M01] - JNK phosphorylation of YAP enhances the stabilization of delta-Np63alpha by direct binding. H357 cells were transfected with control siRNA (siCTL) or YAP siRNA (siYAP) and 72 h later the cells were harvested for IP of endogenous p63. p63 IP eluates and input lysates were analyzed by Western blotting using the indicated antibodies. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis20107) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/YAP1-Antibody-2F12-Knockdown-Validated-H00010413-M01-img0016.jpg "<b>Genetic Strategies Validation. </b>Western Blot: YAP1 Antibody (2F12) - Isoform 5 [H00010413-M01] - YAP1 Antibody (2F12) [H00010413-M01] - JNK phosphorylation of YAP enhances the stabilization of delta-Np63alpha by direct binding. H357 cells were transfected with control siRNA (siCTL) or YAP siRNA (siYAP) and 72 h later the cells were harvested for IP of endogenous p63. p63 IP eluates and input lysates were analyzed by Western blotting using the indicated antibodies. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis20107) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Western Blot: YAP1 Antibody (2F12) [H00010413-M01] - Analysis of YAP1 Antibody (2F12) Isoform 5 expression in Hela S3 N cells. Observed molecular weight 75 kDa.](http://images.novusbio.com/fullsize/YAP1-Antibody-2F12-Western-Blot-H00010413-M01-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: YAP1 Antibody (2F12) [H00010413-M01] - Analysis of monoclonal antibody to YAP1 on HeLa cell. Antibody concentration 30 ug/ml.](http://images.novusbio.com/fullsize/YAP1-Antibody-2F12-Immunocytochemistry-Immunofluorescence-H00010413-M01-img0009.jpg)
![Immunohistochemistry-Paraffin: YAP1 Antibody (2F12) [H00010413-M01] - Analysis of monoclonal antibody to YAP1 on formalin-fixed paraffin-embedded human endometrium. Antibody concentration 3 ug/ml.](http://images.novusbio.com/fullsize/YAP1-Antibody-2F12-Immunohistochemistry-Paraffin-H00010413-M01-img0011.jpg)
![Western Blot: YAP1 Antibody (2F12) [H00010413-M01] - JNK specifically phosphorylates YAP in vivo. HaCaT, U2OS, MCF7 and 293T cell lines were treated with anisomycin or DMSO (control) for 60 min before harvesting. YAP band shift was analyzed as described before and lysates were analyzed by Western blotting with the indicated antibodies. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis20107) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/YAP1-Antibody-2F12-Western-Blot-H00010413-M01-img0017.jpg)
![Western Blot: YAP1 Antibody (2F12) [H00010413-M01] - Immunogen detection using YAP1 antibody (2F12) Isoform 5, observered MW 37.73KDa) .](http://images.novusbio.com/fullsize/YAP1-Antibody-2F12-Western-Blot-H00010413-M01-img0019.jpg)
![Western Blot: YAP1 Antibody (2F12) [H00010413-M01] - Analysis of YAP1 Antibody (2F12) Isoform 5 in transfected 293T cell line. Lane 1: YAP1 transfected lysate (TMW: 54.5 KDa, observed MW 75 KDa). Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/YAP1-Antibody-2F12-Western-Blot-H00010413-M01-img0018.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - CtIP is phosphorylated by CDKs at multiple sites. Myc-BRCA1 and/or HA-CtIP WT or indicated mutants were expressed in 293T cells and co-immunoprecipitation was performed. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pgen.1003277) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0022.jpg "Western Blot: c-Myc Antibody (9E10) [NB600-302] - CtIP is phosphorylated by CDKs at multiple sites. Myc-BRCA1 and/or HA-CtIP WT or indicated mutants were expressed in 293T cells and co-immunoprecipitation was performed. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pgen.1003277) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: c-Myc Antibody (9E10) [NB600-302] - c-Myc was detected in immersion fixed paraffin-embedded sections of human breast cancer using anti-human mouse monoclonal antibody (Catalog # NB600-302, clone 9E10) at 1:50 dilution overnight at 4 C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue). Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Immunohistochemistry-Paraffin-NB600-302-img0009.jpg)
![Simple Western: c-Myc Antibody (9E10) [NB600-302] - Simple Western lane view shows a specific band for c-Myc in 0.5 mg/ml of Jurkat lysate. This experiment as performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Simple-Western-NB600-302-img0006.jpg)
![Western Blot: c-Myc Antibody (9E10) - BSA Free [NB600-302] - Western blotting analysis of unsorted (W) and sorted ROSl degrees w(L) and ROShigh(H) cells. Data shown are representative of at least two independent experiments.DyLight 650 conjugated version of this antibody used (NB600-302C). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25857523/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-BSA-Free-Western-Blot-NB600-302-img0026.jpg)
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody (9E10) [NB600-302] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-c-Myc (9E10) at 10 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Immunocytochemistry-Immunofluorescence-NB600-302-img0011.jpg)
![Flow (Intracellular): c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.. Using the PE format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Intracellular-NB600-302-img0024.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - Analysis of c-myc in Jurkat cell lysates using NB600-302.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0005.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - Flow cytometric analysis of ROS and the mitochondrial status. Western blotting analysis of unsorted (W) and sorted P1 and P2 cells. Data shown are representative of at least two independent experiments. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/ncomms7750) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0025.jpg)
![Flow Cytometry: c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Cytometry-NB600-302-img0014.jpg)
![Flow Cytometry: c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on Jurkat cells with c-Myc Antibody (9E10) NB600-302R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Cytometry-NB600-302-img0019.jpg)
![Flow (Intracellular): c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.. Using the FITC format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Intracellular-NB600-302-img0023.jpg)
![Western Blot: c-Myc Antibody (9E10) - BSA Free [NB600-302] - NLRP2 interacts with SCMC components TLE6, OOEP, FILIA & NLRP5.(A) NLRP2 was overexpressed with myc-tagged OOEP, TLE6, NLRP5 & FILIA in HEK293T cells for 48 hours, immunoprecipitated with anti-NLRP2 or IgG as negative control & immunoblotted with anti-myc. Top panel shows specificity of anti-NLRP2 IP & bottom panel shows that NLRP2 binds to OOEP, TLE6, FILIA & NLRP5. Uncropped, full length western blots have been provided in Supplementary Figure 5. (B) Whole-mount immunofluorescence co-staining with anti-NLRP2 (green) & DAPI (blue) for nuclear staining on Nlrp2+/+ oocytes & embryos at 2-, 4-,16-cell & morula stages revealed a predominantly SCMC-like localization for NLRP2. Scale bars represent 200 μm. (C) Co-staining with anti-TLE6 (green) & DAPI (blue) of paraffin-embedded oocyte sections reveals a typical cortical stain of TLE6 in oocytes of Nlrp2+/+ dams but a more intense & diffuse stain in oocytes of Nlrp2tm1a/tm1a dams. Scale bars represent 10 μm. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/srep44667), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-302_mouse-monoclonal-c-myc-antibody-9e10-310202416163779.jpg)
![Western Blot: c-Myc Antibody [NB600-335] - Detection of c-myc-tagged Protein by Western Blot. Samples: 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibodies: Affinity purified, goat anti-c-myc antibody NB600-335 at 0.04 ug/ml (1:25,000). Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-335-img0006.jpg "Western Blot: c-Myc Antibody [NB600-335] - Detection of c-myc-tagged Protein by Western Blot. Samples: 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibodies: Affinity purified, goat anti-c-myc antibody NB600-335 at 0.04 ug/ml (1:25,000). Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody [NB600-335] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-c-Myc conjugated to Alexa Fluor 488 [NB600-335AF488] at 20 ug/mL for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective. Image using the Alexa Fluor 488 format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Immunocytochemistry-Immunofluorescence-NB600-335-img0007.jpg)
![Western Blot: c-Myc Antibody [NB600-335] - Analysis using the HRP conjugate of NB600-335. Detection of 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibody used at 0.4 ug/mL (1:25,000).](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-335-img0005.jpg)
![Western Blot: p53 Antibody (PAb 240) [NB200-103] - Analysis of p53 in MCF7 and HeLa lystates. Image courtesy of anonymous customer product review.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Western-Blot-NB200-103-img0001.jpg "Western Blot: p53 Antibody (PAb 240) [NB200-103] - Analysis of p53 in MCF7 and HeLa lystates. Image courtesy of anonymous customer product review.")
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - PC12 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-p53 Antibody (PAb 240) NB200-103 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0013.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (PAb 240) [NB200-103] - p53 was detected in immersion fixed paraffin-embedded sections of human prostate cancer using anti-human mouse monoclonal antibody (Catalog # NB200-103) at 1:200 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue). Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunohistochemistry-Paraffin-NB200-103-img0005.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on HeLa cells with p53 Antibody [PAb 240] NB200-103 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-p53 (PAb 240) [NB200-103] at a 1:200 dilution overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-p53 Antibody (PAb 240) NB200-103 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - Neuro2a cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-p53 Antibody (PAb 240) NB200-103 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0012.jpg)
![Flow (Intracellular): p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on HeLa cells with p53 (PAb240) NB200-103 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by APC-conjugated anti-mouse IgG secondary antibody F0101B.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Intracellular-NB200-103-img0003.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on HeLa cells with p53 (PAb240) NB200-103AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0006.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on A549 cells with p53 (PAb240) NB200-103AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0007.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on MCF7 cells with p53 [PAb 240] Antibody NB200-103AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0008.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on Neuro2a cells with p53 Antibody [PAb 240] NB200-103 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0009.jpg)
![Western Blot: RelA/NFkB p65 Antibody [NB100-2176] - Human glomerular endothelial cell lysates, time-response treatment with 10ng/ml TNF-alpha. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-Western-Blot-NB100-2176-img0006.jpg "Western Blot: RelA/NFkB p65 Antibody [NB100-2176] - Human glomerular endothelial cell lysates, time-response treatment with 10ng/ml TNF-alpha. This image was submitted via customer Review.")
![Immunohistochemistry-Paraffin: RelA/NFkB p65 Antibody [NB100-2176] - Staining of formalin-fixed, paraffin-embedded human DLBCL showing nuclear expression of NFkB p65 in the tumor cells.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-Immunohistochemistry-Paraffin-NB100-2176-img0004.jpg)
![Western Blot: RelA/NFkB p65 Antibody [NB100-2176] - Analysis of NFkB p65 expression in A431 (A) and HeLa (B) whole cell lysates.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-Western-Blot-NB100-2176-img0005.jpg)
![Immunohistochemistry-Paraffin: Rabbit Polyclonal RelA/NFkB p65 Antibody [NB100-2176] - RelA/NFkB p65 IHC (brown) in the mice liver tissue; bars, 200 μm. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-2176_rabbit-polyclonal-rela-nfkb-p65-antibody-immunohistochemistry-paraffin-1111202410307..jpg)
![Immunocytochemistry/Immunofluorescence: Rabbit Polyclonal RelA/NFkB p65 Antibody [NB100-2176] - Mice hepatocytes stained for RelA/NFkB p65. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-2176_rabbit-polyclonal-rela-nfkb-p65-antibody-immunocytochemistry-immunofluorescence-2511202410544..png)
![Immunohistochemistry-Paraffin: SOX2 Antibody [NB110-37235] - Staining of human uterus, endometrial glands.](http://images.novusbio.com/fullsize/SOX2-Antibody-Immunohistochemistry-Paraffin-NB110-37235-img0012.jpg)
![Western Blot: SOX2 Antibody [NB110-37235] - Detection of SOX2 in mouse brain lysate using NB110-37235 at 0.5 ug/mL.](http://images.novusbio.com/fullsize/SOX2-Antibody-Western-Blot-NB110-37235-img0008.jpg)
![Flow Cytometry: SOX2 Antibody [NB110-37235] - An intracellular stain was performed on A549 with NB110-37235 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylgiht 550.](http://images.novusbio.com/fullsize/SOX2-Antibody-Flow-Cytometry-NB110-37235-img0015.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: SOX2 Antibody [NB110-37235] - MDA-MB-231 subclones transfected with NTC or HIF-1 alpha shRNA vector were treated with vehicle (V) or paclitaxel (P) and immunoblot assay was performed. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SOX2-Antibody-Western-Blot-NB110-37235-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: SOX2 Antibody - BSA Free [NB110-37235] - Rat FR cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with SOX2 Antibody (NB110-37235) at 2ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/SOX2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-37235-img0019.jpg)
![Flow Cytometry: SOX2 Antibody - BSA Free [NB110-37235] - An intracellular stain was performed on U-251 MG cells with SOX2 Antibody NB110-37235 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/SOX2-Antibody---BSA-Free-Flow-Cytometry-NB110-37235-img0020.jpg)
![Western Blot: SOX2 Antibody [NB110-37235] - Expression of pluripotency factor Sox2 in human head and neck cancer cell lines FaDu and HN5. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SOX2-Antibody-Western-Blot-NB110-37235-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: SOX2 Antibody [NB110-37235] - Staining of SOX2 in NTERA2 cells with Dylight 488 (Green). Alpha-tubulin and nuclei were counterstained with Dylight 550 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/SOX2-Antibody-Immunocytochemistry-Immunofluorescence-NB110-37235-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: SOX2 Antibody [NB110-37235] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-SOX2 (NB110-37235) at a 1:200 dilution overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with and anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/SOX2-Antibody-Immunocytochemistry-Immunofluorescence-NB110-37235-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: SOX2 Antibody - BSA Free [NB110-37235] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with SOX2 Antibody (NB110-37235) at 2ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/SOX2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-37235-img0018.jpg)
![Western Blot: MafA Antibody [NB400-137] - Nuclear extract (6 ug) from HeLa cells transfected with MafA, MafB or cMaf expression constructs. Affinity purified anti-MafA antibody (NB400-137), anti-MafB antibody (NB600-266) or anti-c-Maf antibody (NB600-267). Each antibody was used at 0.5 ug/ml.](http://images.novusbio.com/fullsize/MafA-Antibody-Western-Blot-NB400-137-img0008.jpg "Western Blot: MafA Antibody [NB400-137] - Nuclear extract (6 ug) from HeLa cells transfected with MafA, MafB or cMaf expression constructs. Affinity purified anti-MafA antibody (NB400-137), anti-MafB antibody (NB600-266) or anti-c-Maf antibody (NB600-267). Each antibody was used at 0.5 ug/ml.")
![Immunohistochemistry-Paraffin: MafA Antibody [NB400-137] - Immunohistochemical staining of MafA (blue) and insulin (green) in mouse pancreas. Image from verified customer review.](http://images.novusbio.com/fullsize/MafA-Antibody-Immunohistochemistry-Paraffin-NB400-137-img0009.jpg)
![Western Blot: MafA Antibody [NB400-137] - Binding of MafA to the enhancer region of the endogenous insulin gene. Samples: Immunoprecipitated cross-linked DNA from betaTC-3 cells was analyzed by PCR. As controls, reactions were run with no DNA, with input chromatin, with DNA obtained after precipitation with rabbit IgG or without antibody (lanes 1 through 5, respectively). Antibody: Affinity purified rabbit anti-MafA antibody (NB 400-137).](http://images.novusbio.com/fullsize/MafA-Antibody-Western-Blot-NB400-137-img0007.jpg)
![Gel Super Shift Assays: MafA Antibody [NB400-137] - Electrophoretic Mobility Shift of MafA, MafB and c-Maf. Samples: Nuclear extract (6 ug) from HeLa cells transfected with MafA, MafB or c-Maf expression constructs. Antibodies: Affinity purified anti-MafA antibody NB400-137, anti-MafB antibody NB600-266 or anti-c-Maf antibody NB600-267.](http://images.novusbio.com/fullsize/MafA-Antibody-Gel-Super-Shift-Assays-NB400-137-img0005.jpg)
![Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - HIF-1 alpha induction by CoCl2 on Caki-1 cell lysate. HIF-1 alpha antibody (H1alpha67) [NB100-105]. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0019.jpg "<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - HIF-1 alpha induction by CoCl2 on Caki-1 cell lysate. HIF-1 alpha antibody (H1alpha67) [NB100-105]. Western blot image submitted by a verified customer review.")
![<b>Biological Strategies Validation. </b>Simple Western: HIF-1 alpha Antibody Pack [NB100-900WB] - Simple Western lane view shows a specific band for HIF-1 alpha in 0.5 mg/mL of hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. HIF-1 alpha Antibody [NB100-449].](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Simple-Western-NB100-900WB-img0018.jpg)
![Simple Western: HIF-1 alpha Antibody Pack [NB100-900WB] - Image shows a specific band for HIF-1 alpha in 0.2 mg/mL of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Simple-Western-NB100-900WB-img0022.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Naive CD4 T cells from WT, VHL-deficient (Vhl KO), or HIF-1 alpha-deficient (HIF-1 alpha KO) mice were differentiated under IL-22-skewing conditions for a total of 60 h. Some cells remained at normoxia for the duration of the culture (N); others were at normoxia for 35 h and then hypoxia (1% O2) for 24 h (H). At 60 h, nuclear extracts were harvested, and HIF-1 alpha and Lamin B1 levels were analyzed by Western blot. Image from verified customer review. HIF-1 alpha Antibody (H1alpha67) [NB100-105]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Knockout-Validated-NB100-900WB-img0020.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Normoxic pre-treatment sensitizes glioma cells to radiation after graded chronic hypoxic (GCH) exposure. The results of anchorage-independent colony forming assays are shown for U87, U87-luc, GL261 glioma cells and 0308 GSCs after 5 Gy radiation exposure under varying O2 conditions. For easier comparisons among cell types, raw values are expressed as a % of the cell type's negative (non-irradiated) control and the means & SEMs are plotted. Also shown are Western blots of nuclear HIF-1alpha at the time of irradiation. Corresponding Western blots of lamin A/C are shown as a loading control. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0111199) licensed under a CC-BY license. HIF-1 alpha Antibody [NB100-479]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0015.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Morphological alterations induced by DMOG are HIF-1alpha dependent. glEND.2 cells were stably transfected with shGFP, shHIF-1alpha or shHIF-2alpha. The clones were cultured under normoxic (N) or hypoxic (H, 1% O2) conditions, or treated with DMOG for 6 h. 30 ug protein of cellular protein were loaded for the detection of HIF-1alpha, and nuclear extracts (20 ug protein) were used for the detection of HIF-2alpha. Image collected and cropped by CiteAb from the following publication (//biosignaling.biomedcentral.com/articles/10.1186/1478-811X-11-80) licensed under a CC-BY license. HIF-1 alpha Antibody [NB100-449]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Knockdown-Validated-NB100-900WB-img0017.jpg)
![Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Analysis of HIF-1 alpha in overexpression and endogenous HIF-1 alpha & HIF-2 alpha using anti-HIF-1 alpha antibody NB100-134. The data showed that HIF-1 alpha antibody did not react to HIF-2 alpha overexpression. Wester blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0021.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - HIF-1 alpha induction on Caki-1 cell lysate using CoCl2. Western blot image submitted by a verified customer review. HIF-1 alpha Antibody [NB100-449]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0016.jpg)
![Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Detection of HIF-1 alpha (125-130 kDa) from human placental villous explant total protein. HIF-1 alpha Antibody (HA111) [NB100-296]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0023.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: ATF3 Antibody [NBP1-85816] - ATF3 antibody in indirect immunofluorescence staining of human tumor cells using a green-fluorescent secondary antibody showing nuclear localization. Nuclei stained with DAPI (blue). Image from verified customer review.](http://images.novusbio.com/fullsize/ATF3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-85816-img0028.jpg)
![Immunocytochemistry/Immunofluorescence: ATF3 Antibody [NBP1-85816] - Staining of human cell line A-431 shows localization to nucleus and nucleoli. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/ATF3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-85816-img0012.jpg)
![Immunohistochemistry-Paraffin: ATF3 Antibody [NBP1-85816] - Staining of human fallopian tube shows moderate to strong nuclear positivity in a subset of glandular cells.](http://images.novusbio.com/fullsize/ATF3-Antibody-Immunohistochemistry-Paraffin-NBP1-85816-img0015.jpg)
![Immunohistochemistry-Paraffin: ATF3 Antibody [NBP1-85816] - Staining of human placenta shows strong nuclear positivity in trophoblastic cells.](http://images.novusbio.com/fullsize/ATF3-Antibody-Immunohistochemistry-Paraffin-NBP1-85816-img0016.jpg)
![Immunohistochemistry-Paraffin: ATF3 Antibody [NBP1-85816] - Staining of human urinary bladder shows moderate to strong nuclear positivity in epithelial cells.](http://images.novusbio.com/fullsize/ATF3-Antibody-Immunohistochemistry-Paraffin-NBP1-85816-img0018.jpg)
![Immunohistochemistry-Frozen: ATF3 Antibody [NBP1-85816] - Image was captured under an epi-fluorescent microscope. Alexa 488 conjugated rabbit antibody was used for the secondary antibody. Immunofluorescent signal was localized in the nucleus. Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/ATF3-Antibody-Immunohistochemistry-Frozen-NBP1-85816-img0023.jpg)
![Western Blot: ATF3 Antibody [NBP1-85816] - Usp9X inhibition causes Noxa increase & ER stress in MPNST cell lines. Ultrastructural analysis shows features of paraptosis. (a,b) ST88-14 cells were transfected for 24 h with either non-targeting (NT)-siRNA or Usp9X-siRNA (a) or treated with WP1130 at the concentration of 1.25 & 2.5 µM (b). Whole cell extracts were collected prior to Western blot analysis for ATF3, Noxa & beta -actin. Numbers shows protein quantification analyzed through ImageJ. N = 3. (c–e) Ultrastructural appearance of untreated control cells using TEM. (f–h) After treatment with WP1130 at the concentration of 2.5 µM (f,g,h) T265-2c cells showed extensive cytosolic vacuolization (f, red arrows) & swelling of ER (g, red arrowheads) & mitochondria (h, red arrows). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30478285), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-85816_rabbit-polyclonal-atf3-antibody-310202415171333.jpg)
![Immunocytochemistry/ Immunofluorescence: ATF3 Antibody [NBP1-85816] - Axotomy-induced recombination in peripherally-projecting neurons. A, Validation of an ATF3-specific antibody. The Novus antibody (NBP1-85816) produces a positive signal in nuclei of axotomized sensory neurons in ATF3+/+ mice, but not ATF3cre/cre mice. Note that the Santa Cruz antibody (C-19) labels neuronal nuclei in in the latter (inset), indicating non-specific staining. B, C, Axotomy induced reporter expression in sensory (DRG), sympathetic (stellate ganglion, SG), & motoneurons 4 d after injury. D, Reporter expression in sensory axons & motoneurons one week after injury. E, Preventing CreERT2 translocation from cytoplasm to nucleus with ICI 182780 reduces recombination in ATF3+ cells (by ∼50%). F, Recombination efficiency 16 d after injury was calculated by expressing the proportion of tracer-filled somata (labeled at the time of injury) that were also reporter (tdtomato)-positive. G, Recombination efficiencies at 4 & 16 d after injury (n = 3 for each time point) for DRG & motoneurons. Images in panels A, B, E were taken from whole mounts, those in C, D, F from cryosections. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30993183), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-85816_rabbit-polyclonal-atf3-antibody-31020241613641.jpg)
![Immunohistochemistry: ATF3 Antibody [NBP1-85816] - Nociceptor deletion of Tsc2 preferentially upregulates cJun & Atf3 expression in IB4-positive neurons. A, Immunohistochemistry of L4 DRG contralateral & ipsilateral to a sciatic nerve transection (SN injury) at 3 d post-injury stained for cJun, Isl1 (all neurons), & IB4. Arrows point to cJun-positive, IB4-negative neurons, & arrowheads point to cJun, IB4 double-positive neurons in uninjured Tsc2 cKO DRG. Scale bars: 50 μm. B, Quantification of percentage of cJun-positive neurons from A. C, Immunohistochemistry of L4 DRG for Atf3, Isl1 (all neurons) & IB4. Arrows point to Atf3-positive, IB4-negative neurons & arrowheads point to Atf3, IB4 double-positive neurons in uninjured Tsc2 cKO DRG. Scale bars: 50 μm. D, Quantification of percentage of Atf3-positive neurons from C. E, Western blotting of uninjured control & Tsc2 cKO L4/L5 DRG from mice receiving daily vehicle or rapamycin treatment for 3 d. F, Quantification of protein expression from E. Log2 fold change relative to uninjured control from the same biological replicate. N.S., not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Extended Data Figure 5-1 shows data values of mean & SEM, number of replicates, statistical tests, & values for all comparisons. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31182472), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-85816_rabbit-polyclonal-atf3-antibody-31020241613637.jpg)
![Western Blot: ATF3 Antibody [NBP1-85816] - Nociceptor deletion of Tsc2 preferentially upregulates cJun & Atf3 expression in IB4-positive neurons. A, Immunohistochemistry of L4 DRG contralateral & ipsilateral to a sciatic nerve transection (SN injury) at 3 d post-injury stained for cJun, Isl1 (all neurons), & IB4. Arrows point to cJun-positive, IB4-negative neurons, & arrowheads point to cJun, IB4 double-positive neurons in uninjured Tsc2 cKO DRG. Scale bars: 50 μm. B, Quantification of percentage of cJun-positive neurons from A. C, Immunohistochemistry of L4 DRG for Atf3, Isl1 (all neurons) & IB4. Arrows point to Atf3-positive, IB4-negative neurons & arrowheads point to Atf3, IB4 double-positive neurons in uninjured Tsc2 cKO DRG. Scale bars: 50 μm. D, Quantification of percentage of Atf3-positive neurons from C. E, Western blotting of uninjured control & Tsc2 cKO L4/L5 DRG from mice receiving daily vehicle or rapamycin treatment for 3 d. F, Quantification of protein expression from E. Log2 fold change relative to uninjured control from the same biological replicate. N.S., not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Extended Data Figure 5-1 shows data values of mean & SEM, number of replicates, statistical tests, & values for all comparisons. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31182472), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-85816_rabbit-polyclonal-atf3-antibody-31020241612236.jpg)
![Immunocytochemistry/ Immunofluorescence: ATF3 Antibody [NBP1-85816] - Axotomy does not induce ATF3 in Schwann cells. A, Cryosections from injured DRG (inset) & distal sciatic nerve from the same mouse processed for ATF3 immunohistochemistry (Novus NBP1-85816). B, Punctate staining in the nerve proved to be non-specific fluorescence of leukocytes (note non-nuclear signal in the absence of primary antibody). C, In intact sciatic nerves, cells morphologically identical to Remak cells had at some point undergone recombination. D, Following injury, their numbers increased. E, This was attributable to their proliferation in the injured nerve (as opposed to ATF3 induction & subsequent recombination). C′, D′, Magnification of areas outlined in C & D demonstrate the spindle shaped morphology characteristic of Remak cells. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30993183), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-85816_rabbit-polyclonal-atf3-antibody-310202416121992.jpg)
